Harvard Bioscience (HBIO) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $8.6 million.
- Harvard Bioscience's Cost of Revenue fell 689.84% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.6 million, marking a year-over-year decrease of 745.35%. This contributed to the annual value of $39.4 million for FY2024, which is 1474.7% down from last year.
- According to the latest figures from Q3 2025, Harvard Bioscience's Cost of Revenue is $8.6 million, which was down 689.84% from $8.9 million recorded in Q2 2025.
- In the past 5 years, Harvard Bioscience's Cost of Revenue ranged from a high of $14.8 million in Q3 2022 and a low of $8.6 million during Q3 2025
- Over the past 5 years, Harvard Bioscience's median Cost of Revenue value was $11.6 million (recorded in 2023), while the average stood at $11.4 million.
- Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 3588.66% in 2021, then plummeted by 2789.15% in 2023.
- Over the past 5 years, Harvard Bioscience's Cost of Revenue (Quarter) stood at $13.5 million in 2021, then decreased by 6.68% to $12.6 million in 2022, then fell by 6.08% to $11.8 million in 2023, then fell by 10.85% to $10.5 million in 2024, then fell by 18.73% to $8.6 million in 2025.
- Its Cost of Revenue was $8.6 million in Q3 2025, compared to $8.9 million in Q2 2025 and $9.6 million in Q1 2025.